PMID- 35016420
OWN - NLM
STAT- MEDLINE
DCOM- 20220113
LR  - 20220113
IS  - 2224-5839 (Electronic)
IS  - 2224-5820 (Linking)
VI  - 10
IP  - 12
DP  - 2021 Dec
TI  - Improved efficacy and safety of low-dose oxaliplatin/pegylated liposomal 
      doxorubicin/S-1 regimen in advanced gastric cancer: a cohort study.
PG  - 12821-12830
LID - 10.21037/apm-21-3584 [doi]
AB  - BACKGROUND: Dose-limiting neurotoxicity is the major side effect caused by 
      oxaliplatin treatment. Optimization of oxaliplatin-containing chemotherapeutic 
      regimens may potentially benefit advanced gastric cancer (AGC) patients. We tried 
      to reduce the dose of oxaliplatin and add a drug to compensate for the efficacy. 
      This cohort study evaluated the efficacy and side effects of low-dose oxaliplatin 
      combined with pegylated liposomal doxorubicin and S-1 (D-SOX) as first-line 
      treatment for AGC. METHODS: 64 AGC patients treated in our hospital between 
      January 2015 and December 2018 were included in this study. Among them, 29 cases 
      received standard S-1 and oxaliplatin (SOX) regimen, and 35 cases received D-SOX. 
      Progression-free survival (PFS), overall survival (OS), response rate (RR), and 
      safety were analyzed. DISCUSSION: The median PFS was 7.0 months [95% confidence 
      interval (CI): 5.77 to 8.23 months] in the SOX group and 9.3 months (95% CI: 
      8.145 to 10.45 months) in the D-SOX group (P=0.021). The median OS was 12.5 
      months (95% CI: 7.00 to 17.97 months) in the SOX group and 18.7 months (95% CI: 
      14.485 to 22.9 months) in the D-SOX group (P=0.027). The incidence of 
      treatment-related grade III-IV adverse events (AEs) was less than 10%. The RRs to 
      these 2 regimens were similar (P=0.609). The incidence of neurotoxicity was 
      significantly reduced in the D-SOX group (62.8% vs. 82.7%). CONCLUSIONS: Low-dose 
      oxaliplatin combined with S-1 and pegylated liposomal doxorubicin (PLD) regimen 
      improved OS and PFS, while exhibiting better toxicity profile as compared with 
      standard SOX regimen for AGC.
FAU - Ma, Jian
AU  - Ma J
AD  - Department of Oncology, Changzhou Tumor Hospital Affiliated to Soochow 
      University, Changzhou, China.
FAU - Xiao, Min
AU  - Xiao M
AD  - Department of Oncology, Changzhou Tumor Hospital Affiliated to Soochow 
      University, Changzhou, China.
FAU - Li, Xiaoqian
AU  - Li X
AD  - Department of Oncology, Changzhou Tumor Hospital Affiliated to Soochow 
      University, Changzhou, China.
FAU - Zhao, Qiu
AU  - Zhao Q
AD  - Department of Oncology, Changzhou Tumor Hospital Affiliated to Soochow 
      University, Changzhou, China.
FAU - Ye, Wei
AU  - Ye W
AD  - Department of Oncology, Changzhou Tumor Hospital Affiliated to Soochow 
      University, Changzhou, China.
FAU - Ji, Wenjing
AU  - Ji W
AD  - Department of Oncology, Changzhou Tumor Hospital Affiliated to Soochow 
      University, Changzhou, China.
FAU - Ling, Yang
AU  - Ling Y
AD  - Department of Oncology, Changzhou Tumor Hospital Affiliated to Soochow 
      University, Changzhou, China.
FAU - Yang, Quanliang
AU  - Yang Q
AD  - Department of Oncology, Changzhou Tumor Hospital Affiliated to Soochow 
      University, Changzhou, China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - Ann Palliat Med
JT  - Annals of palliative medicine
JID - 101585484
RN  - 0 (liposomal doxorubicin)
RN  - 04ZR38536J (Oxaliplatin)
RN  - 3WJQ0SDW1A (Polyethylene Glycols)
RN  - 80168379AG (Doxorubicin)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects
MH  - Cohort Studies
MH  - Doxorubicin/analogs & derivatives
MH  - Humans
MH  - Oxaliplatin/therapeutic use
MH  - Polyethylene Glycols
MH  - *Stomach Neoplasms/drug therapy
OTO - NOTNLM
OT  - Oxaliplatin
OT  - SOX
OT  - advanced gastric cancer (AGC)
OT  - pegylated liposomal doxorubicin (PLD)
EDAT- 2022/01/13 06:00
MHDA- 2022/01/14 06:00
CRDT- 2022/01/12 01:00
PHST- 2021/11/02 00:00 [received]
PHST- 2021/12/22 00:00 [accepted]
PHST- 2022/01/12 01:00 [entrez]
PHST- 2022/01/13 06:00 [pubmed]
PHST- 2022/01/14 06:00 [medline]
AID - 10.21037/apm-21-3584 [doi]
PST - ppublish
SO  - Ann Palliat Med. 2021 Dec;10(12):12821-12830. doi: 10.21037/apm-21-3584.